Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment

[1]  J. Gudeman,et al.  Evidence of Accidental Dosing Errors with Immediate-Release Sodium Oxybate: Data from the US Food and Drug Administration Adverse Event Reporting System , 2023, Drugs - Real World Outcomes.

[2]  P. López-Esteban,et al.  Long-term follow-up on the effects of sodium oxybate on daytime sleepiness and sleep architecture in patients with narcolepsy type 1 , 2023, Revista de neurologia.

[3]  C. Kushida,et al.  Preferences for Attributes of Sodium Oxybate Treatment: A Discrete Choice Experiment in Patients with Narcolepsy , 2022, Patient preference and adherence.

[4]  C. Kushida,et al.  Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial , 2022, CNS Drugs.

[5]  M. Thorpy,et al.  Corrigendum to: Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy , 2021, Sleep.

[6]  C. Shapiro,et al.  Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy , 2021, Sleep.

[7]  J. Rowley,et al.  Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. , 2021, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

[8]  C. Tyler,et al.  Pharmacokinetics of FT218, a Once-Nightly Sodium Oxybate Formulation in Healthy Adults. , 2021, Clinical therapeutics.

[9]  G. Plazzi,et al.  A practical guide to the pharmacological and behavioral therapy of Narcolepsy , 2021, Neurotherapeutics.

[10]  M. Thorpy,et al.  Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy , 2020, Sleep.

[11]  C. Drake,et al.  Relationship between sleep efficacy endpoints and measures of functional status and health‐related quality of life in participants with narcolepsy or obstructive sleep apnea treated for excessive daytime sleepiness , 2020, Journal of sleep research.

[12]  Eline van den Broek-Altenburg,et al.  Using discrete choice experiments to measure preferences for hard to observe choice attributes to inform health policy decisions , 2020, Health Economics Review.

[13]  S. Higgins,et al.  Adherence to wakefulness promoting medication in patients with narcolepsy. , 2020, Sleep medicine.

[14]  M. Thorpy.  Recently Approved and Upcoming Treatments for Narcolepsy , 2020, CNS Drugs.

[15]  G. Plazzi,et al.  Long-term compliance, safety, and tolerability of sodium oxybate treatment in patients with narcolepsy type 1: a postauthorization, noninterventional surveillance study , 2018, Sleep.

[16]  C. McHorney,et al.  Impact of once- or twice-daily dosing frequency on adherence to chronic cardiovascular disease medications: A meta-regression analysis. , 2016, International journal of cardiology.

[17]  Y. Dauvilliers,et al.  Treatment Options for Narcolepsy , 2016, CNS Drugs.

[18]  E. Stolk,et al.  Patient and physician preferences for oral pharmacotherapy for overactive bladder: two discrete choice experiments , 2016, Current medical research and opinion.

[19]  Gilbert Abotisem Abiiro,et al.  Developing attributes and attribute-levels for a discrete choice experiment on micro health insurance in rural Malawi , 2014, BMC Health Services Research.

[20]  G. Plazzi,et al.  The burden of narcolepsy with cataplexy: how disease history and clinical features influence socio-economic outcomes. , 2012, Sleep medicine.

[21]  D. Sobieraj,et al.  Dosing frequency and medication adherence in chronic disease. , 2012, Journal of managed care pharmacy : JMCP.

[22]  Andrew Lloyd,et al.  Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[23]  J. Black,et al.  The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy. , 2010, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

[24]  M. Dubinsky,et al.  Effect of medication dosing frequency on adherence in chronic diseases. , 2009, The American journal of managed care.

[25]  Cathy Alessi,et al.  Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. , 2007, Sleep.

[26]  E. Mignot,et al.  Narcolepsy with cataplexy , 2007, The Lancet.

[27]  J. Black,et al.  Sodium oxybate improves excessive daytime sleepiness in narcolepsy. , 2006, Sleep.

[28]  M Ryan,et al.  Using conjoint analysis to elicit preferences for health care , 2000, BMJ : British Medical Journal.

[29]  Evelyn MacLagan,et al.  Narcolepsy , 1929, Edinburgh medical journal.

[30]  M. Thorpy,et al.  Clinical and practical considerations in the pharmacologic management of narcolepsy. , 2015, Sleep medicine.

[31]  The Xyrem®,et al.  A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. , 2005, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

[32]  U.S.Xyrem® Multicenter Study Group.  Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. , 2004, Sleep medicine.

[33]  A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. , 2002, Sleep.